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 ABSTRACT 
 The prevalence of  TP53 mutations greatly varies between tumor types; in multiple 
myeloma (MM) they were rarely detected at presentation, while increased frequency was 
reported with disease progression. Using next-generation sequencing, we analyzed  TP53 
exons 4-9 in a large representative cohort comprising patients with MM at diagnosis and 
more aggressive forms of plasma cell (PC) dyscrasia, identifying mutations in 4/129 
(3%) MM, 6/24 (25%) primary PC leukemia, and 2/10 (20%) secondary PC leukemia 
cases. A similar increase in prevalence associated with disease aggressiveness (5%, 
29.2% and 44%, respectively) was observed for  TP53 deletion. Interestingly, in ﬁ ve 
patients mutations were not concomitant with  TP53 deletion. Furthermore, longitudinal 
analysis revealed the acquisition of  TP53 mutations in three of nineteen cases analyzed 
at relapse. Identiﬁ ed variants were mostly missense mutations concentrated in the 
DNA binding domain, only partly reﬂ ecting the pattern globally observed in human 
cancers. Our data conﬁ rm that  TP53 mutations are rare in MM at presentation and rather 
represent a marker of progression, similarly to del(17p); however, their occurrence even 
in absence of deletions supports the importance of their assessment in patients with PC 
dyscrasia, in terms of both risk stratiﬁ cation and therapeutic implications. 
 INTRODUCTION 
 The tumor suppressor protein p53, encoded by the 
 TP53 gene at chromosome 17p13, mediates the response 
to various stress signals (including DNA damage, oxidative 
stress, ribonucleotide depletion, and deregulated oncogene 
expression), many of which are encountered during tumor 
development and malignant progression [ 1 ]. Loss of p53 
function, due to  TP53 deletions and/or mutations or by 
defects in the signalling pathways upstream or downstream 
of p53, is associated with oncogenesis, cancer progression 
and drug resistance.  TP53 is mutated in about half of human 
cancers, and the prevalence of gene mutations greatly varies 
between different tumor types. 
 Recently, whole exome sequencing (WES) analyses 
in multiple myeloma (MM) [ 2 – 5 ], albeit reporting slightly 
higher mutational frequencies (probably for the extension 
of the analysis to the entire coding sequence and the 
greater sensitivity), conﬁ rmed the ﬁ ndings of the early 
studies [ 6 – 10 ], i.e. that  TP53 mutations are relatively 
rare at presentation (mutation prevalence ranging from 
0% to 9.7% in representative MM patients’ cohorts). 
The frequency of mutations increases with disease stage, 
reaching 25-30% in plasma cell leukemia (PCL) [ 11 ,  12 ], 
and 80% in human myeloma cell lines (HMCLs) [ 13 ]. 
Oncotarget21354www.impactjournals.com/oncotarget
 A strong association has been described 
between  TP53 mutation and del(17p) [ 14 ]. Deletions, 
predominantly monoallelic, of chromosome 17p13 
region containing the  TP53 gene locus occur in about 
10% of untreated MM cases [ 15 – 17 ]; the incidence rate 
reported in PCL ranges from 35% to 75% [ 12 ,  18 ], and is 
particularly high (more than 50%) in HMCLs [ 19 ]. 17p13 
deletion confers a very negative effect on survival [ 20 ], 
displaying the most powerful cutoff for predicting survival 
if the deletion is carried by more than 50% of malignant 
plasma cells [ 21 ]. Finally, a recent study identiﬁ ed  TP53 
as the critical gene of 17p13 deletion in MM [ 22 ]. 
 RESULTS 
 We performed next generation sequencing (NGS) of 
TP53 exons 4-9 on genomic DNA of 151 primary patients 
with plasma cell dyscrasia, including 129 MM and 12 
primary PCL (pPCL) patients at diagnosis, and 10 secondary 
PCL (sPCL) cases (median depth of coverage = 162x). The 
mutational analysis was limited to this portion of the gene 
coding sequence based on the fact that it contains almost 
98% of  TP53 mutations identiﬁ ed in the main published 
whole genome and exome sequencing studies in MM 
[ 2 – 5 ]. Twelve additional pPCL samples have been recently 
subjected to WES analysis [ 11 ]. Globally, in the 163 
tested patients we identiﬁ ed 14 non-synonymous somatic 
variants in 12 cases ( Table 1 ,  Figure 1 ). Ten mutations were 
single nucleotide variations (SNVs), all of which but one 
(introducing a premature stop codon in PCL-037) were 
missense mutations. The remaining four mutations were 
nucleotide deletions involving 2, 6, 10 and 82 base pairs 
respectively, only one of which (6-bp deletion in PCL-
037) caused an amino acid deletion without alteration of 
the reading frame. Exon 8 was the most frequently targeted 
by mutations (5 variants), followed by exons 5 and 7 (3 
variants each), and exons 4, 6 and 10 (one variant each), 
whereas no variants were found in exon 9. Apart from 
the nonsense mutation W91* in case PCL-037 (localized 
in the SH3-like/Pro-rich structural motif) and the 10-nt 
deletion spanning intron 9-exon 10 junction in case PCL-
017, all other variants targeted the DNA binding domain. 
In regards to the four nucleotide deletions identiﬁ ed, only 
one (T155_R156del in PCL-037) is reported in the IARC 
p53 website ( http://www-p53.iarc.fr/index.html ) [ 23 ], and 
none has been described in other MM series. In contrast, 
all ten single nucleotide variations found by us are listed in 
the dataset of somatic mutations in sporadic cancers of the 
IARC database. Each of the variants is carried by a single 
patient in our cohort. 
 Taking advantage of the most recent WES reports 
in MM [ 2 – 5 ], we globally considered the molecular 
spectrum of  TP53 mutations including the results of our 
present series. We evidenced that mutations cluster in 
the DNA binding domain; I195 and R273 are the most 
frequently mutated residues (I195T detected in three 
cases and I195M in one; R273H in two patients, and 
R273L and R273C each in one case), followed by P278 
(P278S recurring twice, and P278L once), R248 (R248Q 
and R248W in one patient each) and E285 (E285K in two 
cases). Contrary to what is globally observed in MM, 
somatic mutations at codon 195 are not among the most 
recurrent in human tumors. Notably, the substitution 
I195T, like other tumorigenic mutations in the β-sandwich 
affecting hydrophobic residues in the protein core, was 
reported to be severely destabilizing [ 24 ], determining 
a half-life of the unfolding of the mutant protein of less 
than one minute at 37°C [ 25 ]. Conversely, R273 is one 
of the six residues identiﬁ ed as hotspots for tumorigenic 
mutations in human cancers; it is generally targeted by two 
predominant substitutions, i.e. R273H and R273C, both 
of which identiﬁ ed in MM cases and preventing DNA 
binding by the isolated core domain [ 24 ]. With regard to 
the amino acid residue 278, it is one of the essential amino 
acids for major groove contacts in the pentamer sequence 
of the consensus DNA binding site [ 26 ]. The substitution 
E285K is the most common  TP53 temperature-sensitive 
mutation (its wild type TP53 activity is reconstituted at 
about 32°C) and is also carried by the RPMI-8226 MM 
cell line [ 13 ,  27 ,  28 ]. Amino acid substitutions R→W 
and R→Q at the hot spot codon 248 both inactivate the 
transactivating functions of wild type TP53, although it 
has been demonstrated that they differently contribute 
to  in vitro malignant behavior of tumor cells through 
gain-of-function properties [ 29 ]. Other codons are 
targeted by single mutational events in each patient’s 
dataset. Furthermore, virtually all the missense mutations 
identiﬁ ed in our study are classiﬁ ed as non-functional [ 23 ] 
in the IARC database (see Materials and Methods). 
 Noteworthy, we detected the occurrence of two 
concomitant  TP53 mutations in two patients of our dataset. 
In particular, PCL-037 carried the nonsense mutation 
W91* at a variant allele frequency (VAF) of 47.3% and 
a 2-aa deletion (T155_R156del) at a VAF of 49.2%, 
suggesting the occurrence of both mutations virtually 
in the entire tumor population (due to the experimental 
design, it is not possible to determine whether the 
mutations are carried on two different chromosomes or on 
the same allele); and MM-213 harbored a 82 nt-deletion 
(at VAF of 8.2%) comprising the last 50 nucleotides 
of exon 7 and the ﬁ rst 32 nucleotides of intron 7 and 
putatively originating an in frame amino acid deletion and 
altered splicing (due to the loss of a splice donor site), 
and a two-nucleotide deletion (at VAF of 2.6%) in exon 8 
causing frameshift (A276Lfs*29). 
 Mutation frequencies were of 3.1% (4/129), 25% 
(6/24), and 20% (2/10) in MM, pPCL and sPCL patients, 
respectively (Freeman-Halton test,  P = 0.0005), in line 
with the notion that  TP53 mutations are associated with 
aggressive forms of plasma cell dyscrasias and have a role 
in tumor progression than initiation [ 6 ,  7 ]. This hypothesis 
was further supported by  TP53 NGS analysis of 19 of our 
Oncotarget21355www.impactjournals.com/oncotarget
patients at relapse/leukemic transformation, revealing 
the acquisition of non-functional missense mutations 
(undetectable in the corresponding samples analyzed 
by NGS at diagnosis) in the DNA binding domain in 
three cases ( Table 1 ,  Figures 1 and  2 ): speciﬁ cally, the 
longitudinal analysis detected the substitutions P278T 
(VAF = 26.3%) in the myeloma patient MM-280 at 
relapse, F270L (VAF = 97%) at the time of leukemic 
transformation in the myeloma patient MM-281, and 
K120E (VAF = 22.1%) in the pPCL patient PCL-038 at 
relapse, respectively. Notably, genome-wide DNA copy 
number data were also available for MM-281, indicating 
two interstitial deletions of 17p arm not involving  TP53 
locus present at sub-clonal level in the sample at onset, 
and then detecting a larger deletion spanning from 
17p12 to 17pter in virtually all cells of the later sample 
(Supplementary Figure S1). 
 We also tested the association between the 
occurrence of  TP53 mutations and common genetic 
abnormalities in MM (i.e. chromosomal translocations 
at  IGH locus, hyperdiploidy, deletions at chromosome 
regions 13q, 17p, and 1p, and gain at 1q), for which the 
entire patients’ cohort was characterized by means of 
ﬂ uorescence  in situ hybridization (FISH) ( Tables 2 and  3 ). 
 IGH translocations (particularly  MAF -translocations) 
were found to be more frequent in  TP53 -mutated cases 
compared with the whole series (92%  versus 50%,  P = 
0.0024).  TP53 mutations were negatively associated with 
hyperdiploid status (no hyperdiploid cases among the 
 TP53 -mutated ones  versus 33% in the entire cohort,  P
= 0.009); the over-representation of PCL patients within 
mutated cases could affect these ﬁ ndings, although 
in part conﬁ rmed in other series [ 30 ]. However, the 
low  TP53 mutation prevalence in MM did not allow 
to limit contingency analyses to this class. As regards 
17p deletion, a strong association of gene mutation 
with the deletion of the remaining allele was observed: 
in fact, deletion of  TP53 locus globally affected 10.6% 
of cases [4.7% (6/128) of MM, 29.2% (7/24) of pPCL 
and 44.4% (4/9) of sPCL patients respectively], while 
its prevalence reached 58% in  TP53 -mutated subset ( P
< 0.0001). Overall,  TP53 inactivation as a result of gene 
deletion and/or mutation occurred in 7% of MM, 37.5% 
of pPCL and 44.4% of sPCL patients; in particular, the 
 Table 1: Summary of  TP53 non-synonymous/indel variants identiﬁ ed by NGS in the present dataset 
 Variant°  cDNA position 
(NM_000546.5) 
 Amino acid 
change 
 IARC 
mut ID ‡ 
 Domain_
function ‡ 
 Structural 
_motif ‡ 
 Transacti-
vation class ‡ 
 Mutated samples 
(VAF) 
 17:7673803G > A  c.817C > T  R273C  3730  DNA binding  L1/S/H2  non-functional  PCL-030 (100%) 
 17:7674947A > G  c.584T > C  I195T  2446  DNA binding  NDBL/beta-sheets  non-functional  PCL-027 (90.9%) 
 17:7673787G > A  c.833C > T  P278L  3817  DNA binding  L1/S/H2  non-functional  PCL-018 (96.1%) 
 17:7670714 _7670723del  c.994-8 _995del  altered splicing  /  /  /  /  PCL-017 (70%) 
 17:7673810A > T  c.810T > A  F270L  3682  DNA binding  NDBL/beta-sheets  non-functional  MM-281_2 (96.8%) 
 17:7674245T > C  c.718A > G  S240G  3146  DNA binding  L2/L3  non-functional  MM-262 (100%) 
 17:7673781C > T  c.839G > A  R280K  3849  DNA binding  L1/S/H2  non-functional  PCL-031 (98.52%) 
 17:7675074C > T  c.538G > A  E180K  2229  DNA binding  L2/L3  partially functional  PCL-012 (95.82%) 
 17:7675232G > T  c.380C > A  S127Y  1339  DNA binding  L1/S/H2  non-functional  MM-375 (93.33%) 
 17:7673767C > T  c.853G > A  E285K  3932  DNA binding  L1/S/H2  non-functional  PCL-004 (72.71%) 
 17:7675144 _7675149delGCGGGT  c.463 _468delACCCGC  T155_R156del  1785  DNA binding 
 NDBL/
beta-sheets  NA  PCL-037 (49.25%) 
 17:7676096C > T  c.273G > A  W91*  922  SH3-like/Pro-rich 
 SH3-like/
Pro-rich  NA  PCL-037 (47.34%) 
 17:7673788G > T  c.832C > A  P278T  3810  DNA binding  L1/S/H2  non-functional  MM-280_2 (26.28%) 
 17:7676011T > C  c.358A > G  K120E  1245  DNA binding  L1/S/H2  non-functional  PCL-038 (22.11%) 
 17:7674149 _7674230del  c.733 _782+32del  altered splicing  /  /  /  /  MM-213 (8.22%) 
 17:7674238C > T  c.725G > A  C242Y  3185  DNA binding  L2/L3  non-functional  MM-343 (10.96%) 
 17:7673794 _7673795delCA  c.825 _826delTG  A276Lfs*29  /  /  /  /  MM-213 (2.65%) 
 °Genomic positions based on hg38.  
‡ Data were obtained from the IARC p53 website ( http://www-p53.iarc.fr/index.html ). 
 Variants indicated in italic were detected in the sample collected at the second timepoint in longitudinally analyzed patients. VAF: variant allele frequency 
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two lesions were simultaneously present respectively in 
0.8%, 16.7% and 22.2% of cases, causing biallelic gene 
inactivation. A fraction of  TP53 mutations co-occurred 
with variants affecting other MM driver genes ( Figure 3 ) 
[ 31 – 33 ]. Indeed, two  TP53 -mutated cases carried also 
mutations in  DIS3 , and another one was simultaneously 
mutated in  TP53 ,  NRAS and  FAM46C genes. However, 
TP53 mutations were not positively associated with 
those of any other gene; on the contrary, the absence 
of  TP53 mutations in  KRAS -mutated cases was deemed 
statistically signiﬁ cant ( P = 0.019). 
 Concerning variant allele frequencies, in mutated 
patients positive for del(17p) VAFs were almost always 
indicative of the exclusive presence of the mutated 
allele; on the contrary, in mutated cases at onset and 
disomic for chromosome 17 VAFs ranged from 2.65% 
to 100%, suggesting the occurrence of minor mutated 
subclones in MM-213 and MM-343; the presence 
of clonal heterozygous mutations in PCL-037; the 
predominance of mutated allele in PCL-004; and 
apparent copy number-neutral loss of heterozigosity 
in MM-262 ( Figure 4 ). As stated above, in the three 
patients longitudinally analyzed and showing in the late 
sample the emergence of  TP53 mutations not visible 
in the earlier sample, VAFs were of 22.1%, 26.3% and 
97%, respectively. 
 Figure 1: Representation of  TP53 mutations identiﬁ ed in MM/PCL patients, including overview of the literature.
Amino acid changes caused by mutations are indicated on the scheme of the structural organization of TP53 protein. In the lower part 
of the ﬁ gure, schematizing  TP53 gene, exons are numbered under the boxes, ﬁ lled with the color corresponding to the encoded domain. 
Somatic mutations identiﬁ ed in the present series (blue) and in the main recent MM datasets are depicted (Chapman  et al , 2011, and Lohr 
et al , 2014, yellow; Walker  et al , 2012, green and Walker  et al , 2015, pink; Bolli  et al , 2014, light blue). Mutations identiﬁ ed in the present 
cohort in patients at relapse are marked by an asterisk. Symbols of mutations are shaped according to their type (see legend in the ﬁ gure). 
 Figure 2:  TP53 mutations during disease progression. Variants reported in the legend were acquired during disease progression, 
being detectable at plotted allele frequencies only in the late sample of longitudinally analyzed patients. 
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 Table 2: Clinical and molecular characteristics of the 12 MM/PCL patients carrying  TP53 mutations 
Sample  Disease 
stage § 
 Variant $  Mutated 
reads (%) 
 AA change  t(4; 14)  t(11; 14)  t(14; 16)  t(14; 20)  del (13)*  del (17p)*  1q gain*  1p loss*  HD ‡ 
 MM-213  MM 
 17:7674149 _7674230del (82)  8.2%  altered splicing 
 -  +  -  -  +  -  -  -  - 
 17:7673794 _7673795del CA  2.6%  A276L fs*29 
 MM-262  MM  17:7674245T>C  100%  S240G  -  -  -  -  -  -  +  -  - 
 MM-343  MM  17:7674238C>T  11%  C242Y  -  +  -  -  -  -  -  -  - 
 MM-375  MM  17:7675232G>T  93.3%  S127Y  +  -  -  -  -  +  -  -  - 
 PCL-004  pPCL  17:7673767C>T  72.7%  E285K  -  -  +  -  -  -  -  -  - 
 PCL-012  sPCL  17:7675074C>T  95.8%  E180K  -  -  +  -  -  +  -  -  - 
 PCL-017  pPCL  17:7670714 _7670723del  70%  altered splicing  -  -  +  -  +  +  +  +  - 
 PCL-018  pPCL  17:7673787G>A  96.1%  P278L  -  +  -  -  +  +  -  -  - 
 PCL-027  pPCL  17:7674947A>G  90.9%  I195T  -  +  -  -  -  +  -  -  - 
 PCL-030  pPCL  17:7673803G>A  100%  R273C  -  -  -  +  +  +  -  -  - 
 PCL-031  sPCL  17:7673781C>T  98.5%  R280K 
PCL-037 pPCL
17:7675144_7675149delGCGGGT 49.2% T155_R156del
 -  -  +  -  -  +  +  -  - 
 17:7676096C>T  47.3%  W91* 
§ MM: multiple myeloma; pPCL: primary plasma cell leukemia; sPCL: secondary plasma cell leukemia. 
$ Genomic positions based on hg38. 
*del(13), del(17), 1p loss and 1q gain were determined by FISH.
‡ HD: presence of the hyperdiploid status on the basis of FISH evaluation criteria. 
 Table 3: Clinical and molecular characteristics of the 163 MM/PCL patients analyzed for  TP53 mutations 
 Characteristic  All patients (n = 163)  TP53 -wild type
(n = 151) 
 TP53 -mutated
(n = 12) 
 P value a 
  n  %  n  %  n  %  
 MM  129  79  125  83  4  33 
 0.0005  pPCL  24  15  18  12  6  50 
 sPCL  10  6  8  5  2  17 
 del(13q)  76  47  71  47  5  42 
 n.s. 
 chr 13 disomic patients  86  53  79  53  7  58 
 del(17p)  17  11  10  7  7  58 
 <0.0001 
 17p disomic patients  144  89  139  93  5  42 
 1q gain  65  42  62  44  3  25 
 n.s 
 1q disomic patients  89  58  80  56  9  75 
 1p loss  18  13  17  13  1  8 
 n.s. 
 1p disomic patients  123  87  112  87  11  92 
 IGH translocation  80  50  69  46  11  92 
 0.0024 
 no  IGH translocation  81  50  80  54  1  8 
 hyperdiploid  49  33  49  36  0  0 
 0.009 
 non-hyperdiploid  100  67  88  64  12  100 
a Signiﬁ cance was assessed by Freeman-Halton extension of Fisher’s exact test for disease type, and by Fisher’s exact test 
for all other variables.  n.s. : not signiﬁ cant. 
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 DISCUSSION 
 In the present study, the use of deep NGS in a 
large representative cohort of MM at diagnosis and 
more aggressive disease stages substantially conﬁ rmed 
the accepted notion that  TP53 mutations in MM at 
presentation are rarely detected, while their frequency 
increases with disease progression. The enhanced 
sensitivity of our analysis, in fact, was not accompanied 
by a substantial increase in the mutation rate observed 
in MM cases, consistent with the fact that we did not 
ﬁ nd many mutations at particularly low allele frequency, 
which could be undetectable by the traditionally used 
Sanger method. Although we cannot exclude that an 
even greater depth of coverage would eventually bring 
out further smaller mutated subclones, this ﬁ nding is 
in line with what reported by other recent NGS studies 
[ 2 ,  3 ,  34 ]. In extra-medullary MM,  TP53 inactivation 
was signiﬁ cantly more frequent, as a result of both 
gene mutations and deletions, conﬁ rming that these 
lesions represent late-progression events. Consistently, 
we noticed the emergence of a mutation in three of 19 
MM/PCL patients analyzed at relapse; despite the NGS 
analysis of the earlier samples, we could not detect at 
onset minor mutant subclones potentially responsible 
for relapse. Concerning deletion of chromosome arm 
17p, its frequency in intra-medullary MM patients 
of our series appears to be lower than that generally 
reported, a ﬁ nding that could be related to different 
sample size and patient selection criteria; a strong, 
albeit not absolute, association of gene mutation with 
the deletion of the remaining allele was observed also 
in our series, in line with previously reported data [ 30 ]. 
As regards pPCL, it is noteworthy that a recent WES 
analysis by our group indicated that  TP53 impairment 
seemed to lie within a more generalized alteration of cell 
cycle checkpoints, which involved other genes among 
which the most frequently mutated were  ATM ,  ATR , 
 CDKN1A and  BRCA1 [ 11 ]. Furthermore, although less 
prevalent in MM, mutations in  ATM or  ATR genes were 
 Figure 3: Heat map distribution of  TP53 ,  DIS3 ,  FAM46C ,  BRAF ,  KRAS and  NRAS gene mutations among MM/PCL 
patients. The rows correspond to the indicated genes, and columns represent individual MM or PCL samples, which are color-coded on 
the basis of gene status (white: wild-type; light red: Sanger-undetectable mutations; dark red: Sanger-detectable mutations). 
 Figure 4: Allele frequency of the  TP53 mutations identiﬁ ed by NGS analysis. Horizontal axis: sample id and carried amino 
acid variant are reported; patients are ordered according to copy number of  TP53 locus (as determined by FISH analysis) and decreasing 
VAF. In case of multiple mutations carried by an individual patient, the bars of the histogram are marked by the same symbol. 
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lately reported to be associated with a negative impact 
on survival of MM patients enrolled onto the NCRI 
Myeloma XI Trial, in which the inability to deliver an 
effective apoptotic response to DNA damage represented 
the most signiﬁ cantly prognostic mutational marker [ 5 ]. 
 Concerning the type of variants, unlike Chng  et al . 
[ 30 ] and more similarly to what reported by Lodé and 
colleagues [ 14 ] and other more recent papers [ 2 ,  3 ,  5 ], 
most of the mutations identiﬁ ed here were single nucleotide 
missense mutations. Differently from many tumor 
suppressor genes, in human cancers  TP53 is actually most 
commonly altered by missense mutations, that not only 
lead to a loss/diminution of the wild type TP53 activity, but, 
since TP53 normally acts as a tetramer, may also function 
as dominant negative inhibitors over any remaining wild 
type TP53 activity, or even give rise to a more aggressive 
tumor proﬁ le through gain of function activity. Gain of 
function roles in different cellular processes have indeed 
been demonstrated for several TP53 mutants also detected 
in MM/PCL of the present and other published datasets 
[ 2 – 5 ] (P151S, R248Q, R248W, R273H, R273C, V274F, 
P278S, and R280K) [ 35 ]. MM-associated  TP53 mutations 
are concentrated in the DNA binding domain, and the 
frequency at which amino acid residues are targeted only 
in part reﬂ ects the one globally observed in human cancers. 
 In conclusion, our data provide further evidence 
that mutations of  TP53 are rare in MM at diagnosis 
and rather represent a marker of progression, as well 
as the deletion of the locus. This would be consistent 
with the hypothesis that defective TP53 may cause 
extramedullary disease [ 20 ]. Surely, alterations of 
 TP53 identify a high-risk population of patients, even 
in the context of molecularly comprehensive risk 
scoring models [ 5 ]. Although the close association 
between mutations and deletions makes it difﬁ cult to 
understand the prognostic contribution of individual 
lesions [ 2 ,  14 ,  30 ], the recently demonstrated 
haploinsufﬁ ciency of the gene [ 22 ] may be responsible 
of TP53 pathway deﬁ ciency whenever the cells don’t 
have two intact copies of the gene (as a result of both 
deletion and mutations). Furthermore, taking into 
consideration the dominant negative effect or gain of 
function of many of  TP53 mutations, TP53 functionality 
appears to be even more compromised. In general, the 
occurrence of mutations even in cases not carrying the 
deletion supports the importance of their assessment in 
MM patients, given that many anti-MM drugs induce 
apoptosis through multiple pathways that are at least in 
part dependent upon functional TP53 activation. 
 MATERIALS AND METHODS 
 Patients 
 The study cohort consisted of a retrospective 
series of 129 multiple myeloma (MM) and 8 primary 
plasma cell leukemia (pPCL) cases at onset, and 10 
secondary PCL (sPCL), admitted to our Institution from 
July 2001 to April 2014. Additional 16 pPCL patients 
belonged to a prospective multicenter clinical trial (RV-
PCL-PI-350, EudraCT N°2008-003246-28) [ 36 ]. All 
the patients included in this study have been previously 
described [ 33 ]. 
 Sample preparation and molecular analyses 
 Highly puriﬁ ed (≥90% in all cases) plasma cells 
(PCs) were obtained from bone marrow specimens 
(collected at the time of diagnosis) using CD138 
immunomagnetic microbeads as previously described 
[ 37 ,  38 ]; 19 cases were re-sampled at relapse/leukemic 
transformation. Genomic DNA was extracted using 
Wizard genomic puriﬁ cation DNA kit (Promega 
Corporation). 
 Mutation analysis 
 NGS of  TP53 exons 4-9 (RefSeq NM_000546.5, 
representing the longer transcript encoding the longest 
protein isoform) was performed on genomic DNA using 
the Genome Sequencer Junior instrument (Roche-454 Life 
Sciences, Penzberg, Germany), as previously described 
[ 39 ]. Further details on primer sequences and sequencing 
protocol are available in the Supplementary Materials 
and Methods and Supplementary Table S1. The obtained 
sequencing reads were mapped to the  TP53 human 
reference sequence (RefSeq NC_000017.11) and analyzed 
by the Amplicon Variant Analyzer (AVA) software version 
3.0 (454 Life Sciences) to establish the variant allele 
frequency. 
 The presence of each obtained non-synonymous 
variant was veriﬁ ed in an independent PCR product by 
conventional sequencing whenever the sensitivity of the 
Sanger method was consistent with the VAF. NGS analysis 
was repeated in case of mutations detected in less than 
10% of sequencing reads. To exclude germline variants, 
we sequenced the matched normal DNA, when available, 
or consulted the International Agency for Research 
on Cancer (IARC) Database ( http://www-p53.iarc.fr ). 
Information about the functional relevance of the detected 
mutations was obtained from IARC database; speciﬁ cally, 
a TP53 mutant was classiﬁ ed as “non-functional” if 
the median of its transcriptional activities measured in 
reporter assays on eight different promoters containing 
TP53-binding sequences was lower than 20% compared 
to the wild type protein. 
 Statistical analysis 
 Contingency analyses were made using two-sided 
Fisher’s exact test ( P value lower than 0.05 was considered 
signiﬁ cant). 
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